ECX Stock Overview
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Epigenomics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.64 |
| 52 Week High | €6.20 |
| 52 Week Low | €1.55 |
| Beta | 0.98 |
| 1 Month Change | -4.66% |
| 3 Month Change | -8.91% |
| 1 Year Change | -45.95% |
| 3 Year Change | -94.16% |
| 5 Year Change | -99.49% |
| Change since IPO | -99.72% |
Recent News & Updates
Shareholder Returns
| ECX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.2% | -4.9% | -1.5% |
| 1Y | -46.0% | -19.9% | 0.9% |
Return vs Industry: ECX underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: ECX underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| ECX volatility | |
|---|---|
| ECX Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ECX has not had significant price volatility in the past 3 months.
Volatility Over Time: ECX's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 18 | Noel Doheny | www.epigenomics.com |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
| ECX fundamental statistics | |
|---|---|
| Market cap | €1.42m |
| Earnings (TTM) | -€4.46m |
| Revenue (TTM) | €339.23k |
4.2x
P/S Ratio-0.3x
P/E RatioIs ECX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECX income statement (TTM) | |
|---|---|
| Revenue | €339.23k |
| Cost of Revenue | €56.91k |
| Gross Profit | €282.32k |
| Other Expenses | €4.75m |
| Earnings | -€4.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -5.13 |
| Gross Margin | 83.22% |
| Net Profit Margin | -1,315.79% |
| Debt/Equity Ratio | -148.3% |
How did ECX perform over the long term?
See historical performance and comparison